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S U M M A R Y
B A C K G R O U N D : Essential TB care in the European
Union/European Economic Area (EU/EEA) comprises
21 standards for the diagnosis, treatment and prevention
of TB that constitute the European Union Standards for
Tuberculosis Care (ESTC).
M E T H O D S : In 2017, we conducted an audit on TB
management and infection control measures against the
ESTC standards. TB reference centres in five EU/EEA
countries were purposely selected to represent the
heterogeneous European TB burden and examine
geographic variability.
R E S U LT S : Data from 122 patients, diagnosed between
2012 and 2015 with multidrug-resistant TB (n ¼ 49),
extensively drug-resistant TB (XDR-TB) (n ¼ 11), pre-
XDR-TB (n ¼ 29) and drug-susceptible TB (n ¼ 33),
showed that TB diagnosis and treatment practices were
in general in agreement with the ESTC.
C O N C L U S I O N : Overall, TB management and infection
control practices were in agreement with the ESTC in
the selected EU/EEA reference centres. Areas for
improvement include strengthening of integrated care
services and further implementation of patient-centred
approaches.
K E Y W O R D S : multidrug-resistant TB; extensively drug-
resistant TB; TB-HIV co-infection; infection control;
workplace safety
TB REMAINS A MAJOR CLINICAL and public
health threat worldwide. In 2016, 58 994 TB cases
were notified in the European Union/European
Economic Area (EU/EEA), with ~4% diagnosed as
multidrug-resistant TB1 (MDR-TB, i.e., Mycobacte-
rium tuberculosis resistant to at least isoniazid and
rifampicin2). Concerns about the clinical manage-
ment of TB in the EU/EEA have been raised. In 2010,
a survey on TB management showed shortcomings in
comparison with international standards of care,
especially in patients with MDR/XDR-TB (extensive-
ly drug-resistant TB; i.e., MDR-TB with additional
resistance to any fluoroquinolone and at least one of
three injectable second-line drugs).3 The results of the
survey informed the development of the European
Union Standards for TB Care (ESTC).4
Since the ESTC publication in 2012, TB care,
prevention and infection control has further devel-
oped. The End TB Strategy has defined global efforts
to eliminate TB (i.e., TB incidence rate ,10 per
100 000 population) by 2035;5 new rapid genetic
testing is readily available to confirm TB and MDR-
TB, new anti-TB drugs and treatment regimens are
being used and new patient-centred approaches have
been identified to support TB patients.6
The aim of the present study was to ascertain
whether the management of TB (both drug-suscepti-
ble and MDR/XDR-TB) in selected EU/EEA settings
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was consistent with standards for TB care, in




A multi-centre survey was performed between July
and September 2017 in five TB reference centres
located in EU/EEA countries with different TB
epidemiological profiles: Centre 1 (southern Europe;
annual TB incidence ,10/100 000; MDR-TB preva-
lence ,5%); Centre 2 (northern Europe; annual TB
incidence ,20/100 000; MDR-TB prevalence ,5%;
Centre 3 (southern Europe; annual TB incidence
.20/100 000, MDR-TB prevalence ,5%); Centre 4
(central Europe; annual TB incidence .20/100 000;
MDR-TB prevalence ,10%); Centre 5 (eastern
Europe [former Soviet Union]; annual TB incidence
.20/100 000; MDR-TB prevalence .10%).
Study population
Medical records of confirmed TB cases with MDR-,
pre-XDR-, XDR- or drug-susceptible TB, diagnosed
between 1 January 2012 and 31 December 2015 and
with definitive treatment outcomes were considered
eligible. Medical records of paediatric TB cases (15
years of age) and confirmed TB cases with any
resistance (i.e., mono-resistance or poly-drug resis-
tance that is not MDR- or XDR-TB) were excluded.
A maximum of 40 medical records per centre were
reviewed. A 3:1 ratio of MDR/XDR-TB and fully
drug-susceptible TB cases (per centre) was pre-
determined. Consecutive cases complying with the
inclusion criteria, starting from those most recently
diagnosed, were selected.
Data collection instruments
Two MS Excel-based forms (MicroSoft, Redmond,
WA, USA) on TB case management and availability of
drugs, used for the survey in 2010, were revised and
updated.7 The revision process included a review of
relevant international guidelines and policy docu-
ments,8–17 and a consultation with a task force
convened by the European Respiratory Society to
support the ESTC update.18,19
New items on diagnosis (e.g., adoption of rapid
molecular tests); treatment (e.g., administration of
delamanid and bedaquiline, implementation of ther-
apeutic drug monitoring) and social protection (e.g.,
use of enablers and material incentives; community-
based support) were included.
The data collection form on TB case management
comprised three sections: 1) characteristics of partic-
ipating centres; 2) patient-level data on TB preven-
tion, diagnosis, treatment and social protection
measures; and 3) assessment of key case management
decisions against the ESTC. The data collection form
on drug availability included three sections: 1)
prescribed treatments and drugs inventory (as report-
ed in mid-2017); 2) financing and procurement
procedures; and 3) national policies and treatment
guidelines (see Supplementary Tables S1–S4).
Data collection
Data were collected by local collaborators and
external auditors. Local collaborators retrieved the
information and filled the Excel databases. Two
external auditors verified the initial data entry and
assessed compliance with the ESTC. The audit team
inspected each facility to assess the infrastructure,
clinical and diagnostic services, patient flow and
infection control measures.
Data analysis
Absolute and relative frequencies (percentages) were
used to describe categorical variables. Means (stan-
dard deviations) or medians (interquartile ranges)
were used to describe continuous numerical variables,
based on their parametric distribution. The collated
data were reviewed against the ESTC standards on
TB diagnosis and treatment (Standards 4, 8, 10–13);
TB-HIV co-infection and other comorbidities (Stan-
dards 14, 15 and 17); and public health and TB
prevention (Standards 18, 20 and 21).4 Compliance
with the ESTC was expressed as a percentage of cases
that met the audit criteria. The performance target
was 100%.
This report follows the guidelines for planning,
implementing and reporting good quality clinical
audits developed by the Healthcare Quality Improve-
ment Partnership.20,21 Each centre received an
individual audit report summarising the main find-
ings, areas of good practice and areas for improve-
ment.
Ethical considerations
Ethical approval was obtained if required by local
legislation. Use of routinely collected data was
authorised by participating institutions. Patient con-
fidentiality was ensured by removing identifiable
personal data. Individual participant consent was not
sought.
RESULTS
Table 1 and Supplementary Tables S5 and S6 provide
a description of the centres selected. Of the 122 TB
cases audited, 33 had drug-susceptible and 89 drug-
resistant TB (Table 2). The targeted sample of 40
medical records per centre was not reached due to
restricted access to medical records (one centre) and
fewer TB cases than expected (three centres).
Most TB patients were hospitalised. Patients with
drug-resistant TB had longer hospitalisation periods,
with a median length of stay ranging between 42 and
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Recording and reporting system
Electronic clinical records for TB patients No Yes Yes Yes Yes
Electronic laboratory registers ? Yes Yes ? ?
Electronic register of contact investigations No Yes Yes No Yes
Laboratory services
Culture methods:
Solid medium (Löwenstein-Jensen) Yes Yes Yes Yes Yes
Liquid, semi-automated system Yes Yes Yes No Yes
NAAT for species identification Yes Yes Yes No* Yes
DST methods
Proportion method Yes Yes Yes Yes Yes
Liquid medium, semi-automated system Yes Yes Yes No Yes
Solid medium, colorimetric method No No No Yes† No
Line-probe assay Yes Yes Yes No Yes
Cartridge-based semi-automated NAAT Yes Yes Yes No* Yes
Availbility of anti-TB drugs















FLD Yes Yes Yes Yes Yes
SLD Yes Yes Yes Yes Yes
Fixed-drug combinations No Yes No Yes Yes
Bedaquiline Yes Yes No Yes Yes
Delamanid Yes Yes Yes Yes Yes
Stock-outs reported during 2016–2017 No No No No No
Infection control measures
Managerial measures
Institutional infection control policy Yes Yes Yes Yes Yes
Infection control committee Yes Yes Yes Yes Yes
Administrative measures
Triage‡ Yes Yes Yes Yes Yes
Education and training of staff Yes Yes Yes Yes Yes
Education of patients Yes Yes Yes Yes Yes
LTBI testing and treatment (for staff) Yes Yes Yes Yes No§
Environmental controls
Negative pressure ventilation system Yes Yes Yes Yes No
Measurement of air changes per hour (frequency) Yes (annual) Yes (constant)¶ Yes (constant)¶ Yes (biannual) NA#
Personal protection
Protective equipment available Yes No** Yes Yes Yes
Surgical mask for patients Yes Yes Yes Yes Yes
Particulate respirators for staff Yes Yes Yes Yes Yes
Particulate respirators for visitors Yes Yes Yes Yes Yes
Respirator fit testing for staff††
Social protection measures
Access to healthcare services
TB diagnosis provided free of charge Yes Yes Yes Yes Yes
TB treatment provided free of charge Yes Yes Yes Yes Yes‡‡
Incentives and enablers
Monthly financial support Yes Yes Yes Yes Yes
Food vouchers — Yes Yes Yes Yes
Transport costs — Yes Yes — Yes
Housing — Yes — —
Social support through:
Hospital-based multidisciplinary teams — Yes Yes — —
Linkage to care with local health services Yes Yes Yes Yes Yes
Integrated community-based case management — Yes Yes — —
* Centre 4 introduced cartridge-based NAAT for species identification and DST after 2015.
† The nitrate reductase assay (also known as Kalfin method) was the DST colorimetric method used in Centre 4.
‡ Defined as prompt identification and separation of people with TB symptoms.
§ In Centre 5, LTBI testing was not done routinely because all staff had been vaccinated using bacille Calmette-Guérin at birth.
¶ A centralised, automated and continuous monitoring system was used in Centres 2 and 3.
# Local exhaust ventilation without high-efficiency particulate air filtration was installed at Centre 5 in the sputum induction rooms. Ultraviolet germicidal
irradiation is available in waiting rooms and corridors.
** In Centre 2, patients with presumptive (smear-positive) TB were isolated in clinic rooms and asked to wear a mask. Patients did not wear surgical masks at the
Outpatient Department to avoid stigma.
†† Respirator fit testing was conducted either when the staff started working in the Centre (Centres 1,4 and 5), annually (Centres 2 and 5) or when changing the
brand of respirators (Centre 1). The frequency of respirator fit testing in Centre 3 was unknown.
‡‡ Patients with multidrug-resistant TB in Centre 5 would seldom need to buy alternative reserve TB drugs, such as thiacetazone, which are neither registered nor
provided by the state.
NAAT ¼ nucleic acid amplification test; DST ¼ drug susceptibility testing; FLD ¼ first-line drug; SLD ¼ second-line drug; LTBI ¼ latent TB infection; NA ¼ not
applicable.
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233 days. In contrast, the median hospitalisation time
for drug-susceptible TB patients ranged between 29
and 80 days. Treatment success rates for all TB cases
ranged between 75% and 100% (Table 3).
All centres had pre-defined diagnostic algorithms
which included chest radiography, smear microscopy
and culture as initial step. The diagnostic algorithms
were adequate (Standard 4, Supplementary Table S7).
Laboratory tests were performed in quality-assured
laboratories. Additional diagnostic imaging (i.e.,
computed tomography) was routine in Centre 5; all
other centres prescribed it occasionally to assess the
extent of lung damage. The tuberculin skin test (TST)
or interferon-gamma release assays (IGRAs) were not
performed within the diagnostic algorithm for active
TB, except for Centre 1. Nearly all drug-susceptible
(n¼7) and few MDR-TB patients (n¼9) in Centre 1
were tested using IGRA alone or TST and IGRA
combined. Nucleic acid amplification tests (NAATs)
were routinely implemented in Centres 1 and 5.
NAATs were not yet available in Centre 4 during the
study period, causing a diagnostic delay of 10–14
days in case of semi-automated liquid culture testing,
and 42–45 days in case of solid culture in Löwenstein-
Jensen medium. The diagnostic algorithm included
sequential drug susceptibility testing (DST) at all
centres, i.e., DST for second-line drugs was per-
formed only for strains with confirmed resistance to
first-line drugs. Most patients with drug-resistant TB
were poly-resistant, i.e., resistant to a mean of 5
(range 2–13) TB drugs. Of those with available
second-line DST results (n¼ 84), 24% were resistant
to fluoroquinolones and 37% to second-line inject-
able drugs.
Treatment was prescribed with the correct regimen,
dosages and duration, regardless of risk factors and
DST pattern (Standards 8 and 12, Supplementary
Table S8). Fixed-dose combinations for first-line























Susceptible 10 (26) 3 (25) 4 (27) 6 (35) 10 (25)
MDR-TB 18 (47) 3 (25) 9 (60) 10 (59) 9 (22.5)
Pre-XDR-TB 9 (24) 4 (33) 2 (13) 1 (6) 13 (32.5)
XDR-TB 1(3) 2 (17) 0 0 8 (20)
Duration of symptoms until diagnosis, days, median [IQR] 90 [45–120] 49 [39–90] 50 [28–139] 180 [60–422] 17.5 [0–30]
Pulmonary TB 38 (100) 9 (75) 13 (87) 17 (100) 40 (100)
Extrapulmonary TB 0 3 (25) 2(13) 0 0
BCG-vaccinated 11 (69)* 2 (33)* Unknown 17 (100) 1†
Previous result of TST recorded 0 0 1 (7) 0 1 (3)
Previous result of IGRA recorded 0 0 1 (7) 0 0
Previous chest radiography result recorded 3 (8) 0 1 (7) 10 (59) 12 (30)
Previous diagnosis of TB 10 (26) 2 (17) 5 (33) 11 (65) 13 (33)
Number of previous anti-TB treatment .1 month, median [IQR] 2 [1–2] NA‡ 1 [1–2.5] 2 [1–3] 1 [1–1]
Number of months between last treatment .1 and current
diagnosis, mean 6 SD
38.8 6 24 NA‡ 207 6 65.3 16.8 6 28.3 88.6 6 70.5
Previous pulmonary surgery 1 (3) 0 0 0 0
Age of patients surveyed in the reference centres, years,
mean 6 SD
38.0 6 13.4 35.1 6 14.6 45.8 6 14.9 47.6 6 12.6 41.1 6 11.7
Males 28 (74) 7 (58) 13 (87) 11 (65) 29 (73)
Foreign-born 32 (84) 12 (100) 3 (20) 0 4 (10)
Unemployed 10 (27)§ 4 (33) 4 (27) 13 (77) 27 (68)
Homeless patients 3 (8) 0 1 (7) 0 7 (18)
Intravenous drug user 2 (5)§ 0 4 (27) 1 (6) 6 (15)
Smoker
Current 14 (39)¶ 2 (18)¶ 5 (38)¶ 12 (71) 28 (80)¶
Former 0¶ 1 (11)# 1 (8)¶ 1 (6) 2 (6)¶
Alcohol abuser
Current 3 (8) 3 (27)** 1 (7) 7 (41) 18 (45)
Former 2 (6)†† 0# 1 (7) 4 (24) 2 (9)††
Incarcerated 3 (8) 0 3 (20) 0 (0) 11 (29)‡‡
* Denominator¼ total number of TB patients for whom data on BCG vaccination were available (Centre 1¼ 16; Centre 2¼ 6).
† Data on BCG vaccination available only for one patient.
‡ Data available for one patient only. The patient was previously treated once, 8 years (96 months) prior to the current diagnosis.
§ Denominator¼ total number of TB patients for whom data on unemployment and use of intravenous drugs were available (Centre 1¼ 37).
¶ Denominator¼ total number of TB patients for whom data on smoking habits were available (Centre 1¼ 36; Centre 2¼ 11, Centre 3¼ 13; Centre 5¼ 35).
# In Centre 2, data on former smoking and alcohol abuse were available for only nine patients.
** Denominator¼ total number of TB patients for whom data on current alcohol abuse were available (Centre 2¼ 11).
†† Denominator¼ total number of TB patients for whom data on previous alcohol abuse were available (Centre 1¼ 32; Centre 2¼ 9, Centre 5¼ 22).
‡‡ Denominator¼ total number of TB patients for whom data on incarceration were available (Centre 5¼ 38).
DR-TB¼drug-resistant TB; MDR-TB¼multidrug-resistant TB; XDR-TB¼extensively drug-resistant TB; IQR¼ interquartile range; BCG¼bacille Calmette-Guérin;
TST¼ tuberculin skin test; IGRA¼ interferon-gamma release assay; SD¼ standard deviation.
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drugs were used at two centres and bedaquiline had
been introduced in four centres.
Most patients received at least one type of
financial, psychological or social support to facilitate
their adherence to treatment (Standard 9, Supple-
mentary Table S8). Treatment monitoring through
monthly follow-ups using both sputum smear mi-
croscopy and culture (Standard 10) was not imple-
mented universally. Centres 1 and 2 in particular did
not follow this standard. Aiming at early detection of
relapse, some centres followed up (once or twice a
year) MDR-TB patients during a total period of 2–5
years after treatment completion.
Management of adverse events was adequate
(Standard 12). Most patients on second-line treat-
ment (85%) had adverse events requiring dose
adjustment or replacement with alternative drugs.
Therapeutic drug monitoring/pharmacokinetics was
done to guide dosing of injectable drugs (eight MDR-
TB patients in Centre 2; one MDR-TB patient in
Centre 3) and antiretroviral treatment (ART) (one
patient with MDR-TB-HIV co-infection in Centre 3).
Management of TB and HIV co-infection (Stan-
dards 14 and 15) was well implemented, with all
patients being offered HIV testing and put on ART
when needed in four centres, and almost all in Centre
5 (Supplementary Table S9). All centres reported
well-coordinated TB-HIV collaborative activities
during hospitalisation. Almost all centres offered
integrated ambulatory care for patients with TB-HIV
co-infection (Centres 1–4). Comorbidities other than
HIV (Standard 17) were also routinely assessed,
except for hepatitis in Centre 5.
An electronic TB register was maintained in three
centres, providing case-based data for monitoring
and evaluation, and allowing for reporting treatment
outcomes (Standard 21). Medical records had com-
plete information on prescribed medications, bacte-
riological response and adverse reactions for all
patients (Standard 13). However, laboratory results
were not always easily accessible in each patient’s file.
All patients had a correct treatment outcome docu-
mented in their files (Supplementary Table S9).
Contact investigation was performed for close
contacts of all TB patients included in the audit
(Standard 18, Supplementary Table S10). Infection
control plans/policies with managerial (e.g., infection
control committees and planning), administrative

















Hospital stay 10 (100) 0 1 (25)* 6 (100) 10 (100)
Total time in hospital, days, median [IQR] 29 [27–37] NA NA 68 [64–86.0] 80 [45–92]
Time to sputum smear conversion, days,
median [IQR]
27 [17–82] NA† NA* 30 [30–60] 40 [31–63]
Time to culture conversion, days, median [IQR] 60.0 [60.0–95.0] NA† 15.0 [10.0–60.0] 45.0 [30.0–90.0] 60.0 [49.5–84.5]
Final outcome
Cured 8 (80) — 2 (50) 6 (100) 9 (90)
Treatment completed 2 (20) 3 (100) 1 (25) — —
Treatment success 10 (100) 3 (100) 3 (75) 6 (100) 9 (90)
Treatment failed — — — — —
Died — — 1 (25) — —
Lost to follow-up — — — — 1 (10)











Drug-resistant TB patients (i.e., MDR-TB, pre-XDR-TB and XDR-TB)
Hospital stay 28 (100) 7 (78) 9 (82) 11 (100) 29 (97)
Total time in hospital, days, median [IQR] 42 [27–71] 96 [54–146] 96 [52–107] 233 [209–262] 109 [55–356]
Time to sputum smear conversion, days,
median [IQR]
42 [28–60] 43 [18–146] 32 [30–91] 60 [60–60] 395 [29–77]
Time to culture conversion, days, median [IQR] 60 [30–90] 75 [41–146] 60 [32–91] 60 [60–60] 57 [36–92]
Final outcome
Cured 20 (71) 3 (33) 7 (64) 9 (82) 23 (77)
Treatment completed 1 (4) 6 (67) 2 (18) — —
Treatment success 21 (75) 9 (100) 9 (82) 9 (82) 23 (77)
Treatment failed 1 (4) — — — —
Died — — — — 2 (7)
Lost to follow-up 3 (11) — — 2 (18) 5 (17)
Transferred out 3 (11) — 2 (18) — —
* In Centre 3, one drug-susceptible TB patient was hospitalised during 29 days. The patient’s initial smear microscopy was negative and the culture was positive.
† In Centre 2, one of the three drug-susceptible TB cases had extrapulmonary TB. Data on sputum smear and culture conversion were unknown for the other two
cases.
IQR¼ interquartile range; NA¼ not applicable; MDR-TB¼multidrug-resistant TB; XDR-TB¼ extensively drug-resistant TB.
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(e.g., latent TB infection [LTBI] screening among
staff), environmental (i.e., methods used to decrease
quantity of droplet nuclei and to control their
direction in the air), and personal protection mea-
sures (e.g., availability of respirators) were available
at all centres (Standard 20, Table 1 and Supplemen-
tary Table S10), although coverage/implementation
varied (Supplementary Tables S5 and S6). At Centre
4, healthcare staff received training in infection
control, and if necessary, additional training on
guidelines for TB detection to decrease diagnostic
delay among symptomatic respiratory patients.
Screening for LTBI among healthcare staff, with
either TST or IGRA, was routinely done at four
centres for occupational health reasons.
DISCUSSION
This survey aimed at assessing TB management in
different EU/EEA settings against international stan-
dards for TB care that were relevant to the study
period. Our results showed good adherence to the
ESTC in selected TB reference centres. TB case
management, with special focus on MDR/XDR-TB,
was conducted to a very large extent according to
standards for TB care. Similarly, infection control
measures were largely implemented according to
national and international guidelines.
Several good practices were reported. TB diagnosis
was performed using quality-assured and up-to-date
laboratory tests. Treatment regimens were adequate
and were based on correct dosages. Introduction of
bedaquiline enabled treatment of pre-XDR-TB and
MDR/XDR-TB patients, in line with international
recommendations.22–24 Other practices such as rec-
ord keeping, can be further improved. Although case-
based records provided detailed accounts of the
clinical history, these did not always include notes
on social and financial support. Similarly, although
patient-centred care provided, its implementation
varied according to local arrangements.
A similar audit conducted in 2009–2010 identified
several problem areas: 1) surveillance (i.e., missing
information on final outcome); 2) infection control
(i.e., deficient implementation of administrative and
environmental measures); 3) clinical management of
TB (i.e., inadequate diagnosis and treatment proce-
dures); 4) clinical management of HIV (i.e., sub-
optimal HIV counselling and testing, and inadequate
ART treatment); 5) laboratory support (i.e., sub-
optimal/not quality-assured laboratory practices); 6)
diagnostic and treatment algorithms (i.e., limited
implementation of rapid diagnostic tools); 7) guide-
lines (i.e., lack of updated, evidence-based guide-
lines); 8) drugs (i.e., limited availability of all first-
and second-line drugs); and 9) funding (i.e., insuffi-
cient resource availability for TB prevention and
control activities).3
Our results show a considerable improvement in
TB prevention, care and infection control when
compared to the previous audit. We acknowledge
that not all previously recruited reference centres
were included in our study. However, countries with a
similar geographic location and TB incidence were
enrolled to obtain comparable results. Few areas still
require attention. For example, different algorithms
for diagnostic testing were used. NAATs for initial
diagnosis and DST were not routinely available at all
centres, resulting in a prolonged wait time for results.
Timely and universal access to NAATs depends not
only on the availability of tests, but also on adequate
infrastructure, use of standard operating procedures,
and sufficient human and financial resources to
ensure sustainability.17,25
Large differences in hospitalisation periods were
also observed. Although TB treatment was initiated
during hospital admission in all centres, patients with
drug-susceptible and -resistant TB in Centres 4 and 5
remained hospitalised for longer periods. Reduction
of hospitalisation length and implementation of
community-based models for ambulatory care are
cost-effective approaches for the provision of MDR-
TB treatment.26,27 Development of context-specific
criteria for hospital admission and discharge, and
ambulatory management of MDR-TB patients have
been suggested for EU countries to minimise trans-
mission and contribute to workplace safety.25
Few patients were lost to follow-up or transferred
out. The majority of those lost to follow-up were
reported from Centre 5. This centre also reported
limited patient-centred actions to support treatment
adherence. The division between medical and social
approaches for the delivery of TB care has previously
been highlighted as an important issue.28 Fragmen-
tation of support indicates neglect of the social and
structural vulnerabilities of TB patients and contrib-
utes to loss to follow-up.28 Conversely, provision of
psychosocial support during treatment improves
treatment adherence and retention in care among
MDR-TB patients.29 A blueprint promoting the
uptake and scale-up of people-centred models of care
has been developed to inform policy-makers and
relevant stakeholders.30
As part of this people-centred model of care,
integrated treatment of TB and comorbidities needs
to be improved. In our study, TB patients were offered
HIV testing and counselling as recommended in
international guidelines.6 However, patients with
TB-HIV co-infection were not always offered ART
and had to visit separate TB and HIV clinics after
hospital discharge. Due to the overlap of risk factors
in populations at-risk for TB and hepatitis B and C, it
is also likely that TB patients co-infected with
hepatitis B and C virus were undiagnosed.31
The use of well-known standards of care (i.e.,
ESTC) and the inclusion of senior consultants with
TB management in the EU/EEA 131
many years of experience in treating MDR-TB
patients in the data collection teams contributed to
the reliability of our findings. However, we were not
able to assess all aspects of TB care in this audit. For
example, while information on support provided to
foster adherence to treatment was collected, there
was no assessment as to whether all patients who
needed support received it.
A limitation of our study is the potential sampling
bias, introduced by the selection strategy of the TB
reference centres. However, different at-risk popula-
tions were captured by varying the study settings,
such as migrants, including EU and non-EU citizens
among those foreign-born; people who inject drugs;
and homeless people. Some of the selected centres
were regional TB reference centres. Results obtained
from regional centres may not be generalisable to
national level. Although the audit results were shared
with local collaborators, the planning and implemen-
tation of a quality improvement action plan were
outside the scope of the present study.
In conclusion, the centres included in this study
reported good adherence to the standards for TB care
recommended for the EU/EEA. Accessible and integrat-
ed services for screening and treatment of LTBI and
active TB that are responsive to the social vulnerabilities
and comorbidities affecting TB patients are needed to
reach TB elimination in the EU/EEA.
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R É S U M É
C O N T E X T E : Les normes de soins de la TB de l’Union
Européenne (ESTC) résument le niveau essentiel des
soins de la TB dans l’Union Européenne/la Zone
Economique Européenne (EU/EEA) en 21 normes de
diagnostic, de traitement et de prévention de la TB.
M É T H O D E S : En 2017, nous avons réalisé un audit de la
prise en charge de la TB et des mesures de lutte contre
l’infection par rapport aux normes de l’ESTC. Les
centres de référence TB de cinq pays d’EU/EEA ont été
sélectionnés pour représenter le poids hétérogène de la
TB en Europe et la variabilité géographique.
R É S U LTAT S : Les données de 122 patients, ayant eu,
entre 2012 et 2015, un diagnostic de TB multirésistante
(n¼49), extrêmement résistante (XDR-TB) (n¼11), TB
pré-XDR (n ¼ 29) et pharmacosensible (n ¼ 33) ont
montré que les pratiques du diagnostic et du traitement
de la TB ont généralement été en accord avec l’ESTC.
C O N C L U S I O N : Dans l’ensemble, la prise en charge de
la TB et les mesures de lutte contre l’infection ont été en
accord avec l’ESTC dans les centres de référence
sélectionnés de l’EU/EEA. Les domaines restant à
améliorer sont le renforcement des services de prise en
charge intégrée et la mise en œuvre accrue d’approches
centrées sur le patient.
R E S U M E N
M A R C O D E R E F E R E N C I A: Los estándares europeos para
el tratamiento de la TB (ESTC) resumen la atención
básica de la TB en la Unión Europea y el Espacio
Económico Europeo (UE/EEE) en 21 normas para el
diagnóstico, el tratamiento y la prevención de la TB.
M É T O D O: En el 2017, se llevó a cabo un examen del
tratamiento de la TB y las medidas de control de
infecciones con respecto a los ESTC. Se escogieron de
manera deliberada centros de referencia de TB en cinco
paı́ses de UE/EEE que representaran la heterogeneidad
de la carga de morbilidad por TB y la variabilidad
geográfica.
R E S U LT A D O S: Los datos de 122 pacientes
diagnosticados entre el 2012 y el 2015 con TB
multirresistente (n ¼ 49), TB ultrarresistente (XDR-
TB) (n¼ 11), TB pre-XDR (n¼ 29) y TB sensible (n¼
33) pusieron en evidencia que, en general, las prácticas
de diagnóstico y tratamiento de la TB eran conformes
con los ESTC.
C O N C L U S I Ó N: En general, las prácticas de tratamiento
de la TB y de control de infecciones en los centros de
referencia escogidos de la UE/EEE están en consonancia
con los ESTC. Las esferas que pueden mejorarse son el
fortalecimiento de los servicios integrados de atención y
una mayor aplicación de los enfoques centrados en el
paciente.
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